Department of Biosciences, School of Science, Indrashil University, Rajpur, Mehsana, Gujarat, India.
The J. David Gladstone Institutes, San Francisco, CA, United States.
Prog Mol Biol Transl Sci. 2021;180:141-151. doi: 10.1016/bs.pmbts.2021.01.008. Epub 2021 Feb 15.
The advancement gained over the past couple of decades in clustered regularly interspaced short palindromic repeats and CRISPR associated proteins (CRISPR-Cas) systems have revolutionized the field of synthetic biology, therapeutics, diagnostics and metabolic engineering. The technique has enabled the process of genome editing to be very precise, rapid, cost-effective and highly efficient which were the downfalls for the previously debuted zinc finger nucleases (ZFN) and transcription activator-like effector nucleases (TALEN) technologies. However, despite its great potential, challenges including off-target activity, method of delivery, ethical and regulatory issues still remain unresolved for the CRISPR-Cas systems. In this chapter, we present and point out the obstacles faced in implementation of the CRISPR-Cas system along with its future prospects.
在过去几十年中,在成簇规律间隔短回文重复序列和 CRISPR 相关蛋白(CRISPR-Cas)系统方面取得的进展彻底改变了合成生物学、治疗学、诊断学和代谢工程领域。该技术使基因组编辑过程变得非常精确、快速、具有成本效益且高效,而这些正是以前推出的锌指核酸酶(ZFN)和转录激活因子样效应物核酸酶(TALEN)技术的不足之处。然而,尽管具有巨大的潜力,但 CRISPR-Cas 系统仍存在一些挑战,包括脱靶活性、递送方法、伦理和监管问题。在本章中,我们介绍并指出了在实施 CRISPR-Cas 系统时面临的障碍及其未来前景。